<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333332</url>
  </required_header>
  <id_info>
    <org_study_id>15050</org_study_id>
    <nct_id>NCT01333332</nct_id>
  </id_info>
  <brief_title>Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer</brief_title>
  <official_title>Phase II Trial of Accelerated Fraction Radiotherapy With Concomitant Capecitabine as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and to obtain preliminary estimates of the&#xD;
      rate of major pathologic response of neoadjuvant accelerated fraction, standard dose&#xD;
      radiation given with chemotherapy in patients with locally advanced pancreas cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of neoadjuvant accelerated fraction standard dose radiotherapy to 50 Gy with concomitant capecitabine in patients with resectable and borderline resectable pancreas cancer.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine, Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine</description>
    <arm_group_label>Capecitabine, Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard Dose Acclerated Fraction Radiotherapy</intervention_name>
    <description>Standard dose accelerated fraction radiotherapy</description>
    <arm_group_label>Capecitabine, Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. Clinically staged I-III, pathologically confirmed adenocarcinoma of the pancreas.&#xD;
             Mixed (e.g. adeno-squamous, neuroendocrine features) and/or poorly differentiated&#xD;
             carcinomas are eligible as long as the carcinoma is not a predominantly neuroendocrine&#xD;
             carcinoma. Cancers must be deemed by multidisciplinary assessment at UVA to be either&#xD;
&#xD;
               -  Resectable&#xD;
&#xD;
                    -  No overt evidence of vascular involvement&#xD;
&#xD;
                    -  No overt metastatic disease&#xD;
&#xD;
               -  Borderline Resectable, meeting one of the following categories:&#xD;
&#xD;
                    -  Local tumor characteristics:&#xD;
&#xD;
                         -  Abutment of &lt;180◦ of the superior mesenteric artery and/or celiac axis&#xD;
&#xD;
                         -  Abutment or encasement of a short segment hepatic artery&#xD;
&#xD;
                         -  Involvement of the portal vein or superior mesenteric vein amenable to&#xD;
                            vascular reconstruction&#xD;
&#xD;
                    -  Concern for extra pancreatic metastatic disease&#xD;
&#xD;
                         -  indeterminant nodule on imaging&#xD;
&#xD;
                         -  Pathologically confirmed N1&#xD;
&#xD;
                    -  Borderline performance status or medical comorbidities as determined by&#xD;
                       investigators to be concerning for patient's ability to tolerate pancreatic&#xD;
                       resection&#xD;
&#xD;
               -  Patients with overtly unresectable disease are ineligible&#xD;
&#xD;
          2. No prior therapy for pancreatic cancer, including surgery, radiation, or chemotherapy&#xD;
&#xD;
          3. ≥18 years of age&#xD;
&#xD;
          4. Able to provide informed consent and comply with study procedures&#xD;
&#xD;
          5. Concurrent therapy with warfarin is permitted, but INR must be checked weekly&#xD;
&#xD;
          6. Concurrent therapy with phenytoin is permitted, but phenytoin levels must be checked&#xD;
             weekly.&#xD;
&#xD;
          7. Concurrent therapy with CYP2C9 substrates is permitted but discouraged. Patients&#xD;
             taking fluoxetine, glipizide, losartan, voriconazole, or other CYP2C9 substrates&#xD;
             should consider switching to an alternative medication if feasible. (see Appendix 11.3&#xD;
             for a list of CYP2C9 substrates).&#xD;
&#xD;
          8. Adequate organ function:&#xD;
&#xD;
               -  Hematologic&#xD;
&#xD;
                    -  ANC ≥ 1.5 x 10^9 cells/liter&#xD;
&#xD;
                    -  Plts ≥ 100,000 x 10^9 cells/liter&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Total bilirubin ≤ 5 fold the upper limits of normal for laboratory if due to&#xD;
                       biliary obstruction secondary to disease. For patients with total bilirubin&#xD;
                       3-5 times the upper limit, attempt to relieve biliary obstruction is&#xD;
                       required&#xD;
&#xD;
                    -  AST/ALT ≤ 5 fold the upper limits of normal for laboratory&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Creatinine clearance as measured by Cockcroft-Gault (APPENDIX) of &gt;30&#xD;
                       mL/min.&#xD;
&#xD;
                    -  Patients with creatinine clearance of 30-50 mL/min require 25% reduction of&#xD;
                       capecitabine dose.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. No pregnant or lactating women. Women of child bearing age must have a negative&#xD;
             pregnancy test within seven days of beginning therapy and agree to use reliable&#xD;
             contraception for the duration of the study period.&#xD;
&#xD;
          2. No comorbid condition which is deemed by the investigator to have a life expectancy of&#xD;
             less than 6 months&#xD;
&#xD;
          3. No other malignancy diagnosed within the past 5 years, excepting all in situ cancers&#xD;
             and invasive nonmelanomatous skin cancers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanna K. Sanoff, MD</last_name>
    <phone>434-243-6454</phone>
    <email>hsanoff@Virginia.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Yarde, MS</last_name>
      <phone>434-243-8588</phone>
      <email>ery7b@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Hanna K. Sanoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hanna K. Sanoff, MD, Assistant Professor, Principal Investigator</name_title>
    <organization>University of Virginia, Department of Medicine, Hematology and Oncology</organization>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

